id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S17269 R72292 |
Madley-Dowd_UK (Pregabalin) (Controls unexposed, general pop) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Mean 5 years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 0.56 [0.04;9.01] C | 0/408 1,119/514,066 | 1,119 | 408 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12754 R48120 |
Bjørk (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up pregabalin, 5.2 (2.7-7.5) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
0.88 [0.34;2.30] C excluded (control group) |
5/1,666 27/7,950 | 32 | 1,666 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12755 R48123 |
Bjørk (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up pregabalin, 5.2 (2.7-7.5) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
1.01 [0.42;2.43] excluded (control group) |
5/1,666 16,384/4,463,879 | 16,389 | 1,666 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12756 R48126 |
Bjørk (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up pregabalin, 5.2 (2.7-7.5) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 0.47 [0.19;1.14] C | 5/1,666 139/21,634 | 144 | 1,666 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10100 R36799 |
Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.60 [0.20;1.80] excluded (control group) |
7/1,627 15/2,916 | 22 | 1,627 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8541 R28345 |
Coste (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.70 [0.80;3.60] | 7/1,627 3,398/1,710,441 | 3,405 | 1,627 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 0.87 [0.31;2.44] | 4,668 | 3,701 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Pregabalin) (Controls unexposed, general pop) (Mixed indications; 2: Controls unexposed, sick) (Mixed indications; 3: Controls unexposed, NOS) (Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10100, 12754, 12755